ALT
Altimmune, Inc. Common Stock
stockNASDAQ
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual's immune system against multiple target antigens instead of just one. altimmune's respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin's product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.74 | 2026-10-02 | -4.21% | 0.688 |
| 1M | 3.29 | 2026-09-10 | -20.36% | 1.314 |
| 3M | 3.05 | 2026-07-10 | -14.10% | 1.325 |
| 6M | 3.24 | 2026-04-10 | -19.14% | 1.461 |
| 1Y | 3.92 | 2025-10-10 | -33.16% | 1.575 |
| 2Y | 6.02 | 2024-10-10 | -56.48% | — |
| 5Y | 12.38 | 2021-10-11 | -78.84% | 1.332 |
Altimmune, Inc. Common Stock (NASDAQ:ALT) stock price today is $2.62, and today's volume is 2,677,746. ALT is up 0.769% today. The 30 day average volume is 3.93M. ALT market cap is $509.64M with 194.52M shares outstanding.